ABL1 and chronic myelogenous leukemia, BCR-ABL1 positive: In this regard, it was reported that combining asciminib with the ATP-competitive inhibitors nilotinib (14, 17) or ponatinib (17) enhances Abl1 kinase inhibition and suppresses the emergence of resistance in Ph+ leukemia cells isolated from blood of CML patients (17) as well as in KCL-22 mouse xenograft models (14).